CIK 0001737953
- Non-accelerated filer
- Smaller reporting company
Replimune Group, Inc.
Sign in to watch- Ticker
- REPL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Mar 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 822082553
- Phone
- +1 781-222-9600
- Business address
- 500 UNICORN PARK, WOBURN, MA, 01801
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $521,860
- in 2 filings
Net −$521,860. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 83 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-04-01 | Love Colin Chief Operating Officer | Grant or award | +40,000 | 805,735 | ||
| 2023-04-01 | Love Colin Chief Operating Officer | Grant or award · Employee Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2023-04-01 | Lewis Tanya Chief Dev. Op. Officer | Grant or award | +40,000 | 160,360 | ||
| 2023-04-01 | Lewis Tanya Chief Dev. Op. Officer | Grant or award · Employee Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2023-04-01 | Patel Sushil Chief Strategy Officer | Grant or award | +40,000 | 170,146 | ||
| 2023-04-01 | Patel Sushil Chief Strategy Officer | Grant or award · Employee Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2023-04-01 | Coffin Robert President & Chief R&D Officer | Grant or award | +45,000 | 1,841,197 | ||
| 2023-04-01 | Coffin Robert President & Chief R&D Officer | Grant or award · Employee Stock Option (right to buy) | +67,500 | 67,500 | ||
| 2023-04-01 | Astley-Sparke Philip Chief Executive Officer | Grant or award | +142,100 | 1,543,180 | ||
| 2023-04-01 | Astley-Sparke Philip Chief Executive Officer | Grant or award · Employee Stock Option (right to buy) | +213,150 | 213,150 | ||
| 2022-12-09 | Esposito Pamela Chief Business Officer | Option exercise | +15,000 | $1.01 | $15K | 244,402 |
| 2022-12-09 | Esposito Pamela Chief Business Officer | Sale | −15,000 | $25.03 | $375K | 229,402 |
| 2022-12-09 | Esposito Pamela Chief Business Officer | Option exercise · Employee Stock Option (right to buy) | −15,000 | 36,203 | ||
| 2022-12-01 | Xynos Konstantinos Chief Medical Officer | Grant or award | +17,500 | 70,798 | ||
| 2022-12-01 | Xynos Konstantinos Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +26,250 | 26,250 | ||
| 2022-05-16 | Love Colin Chief Operating Officer | Sale | −6,324 | $14.59 | $92K | 765,735 |
| 2022-05-16 | Esposito Pamela Chief Business Officer | Sale | −3,507 | $14.59 | $51K | 229,402 |
| 2022-05-16 | Franchi Jean M. Chief Financial Officer | Sale | −3,436 | $14.59 | $50K | 95,099 |
| 2022-05-16 | Lewis Tanya Chief Dev. Op Officer | Sale | −5,473 | $14.59 | $80K | 120,360 |
| 2022-05-16 | Patel Sushil Chief Commercial Officer | Sale | −10,687 | $14.59 | $156K | 130,146 |
Page 9 of 19 · 365 trades